Oss, The Netherlands, March 20, 2020 —www.citryll.com Citryll announced today that a landmark scientific paper has been published in Nature’s Cellular and Molecular Immunology journal, to be found at https://doi.org/10.1038/s41423-020-0381-3.
“This peer reviewed scientific publication forms the foundation of our CIT-013 drug
development programme. CIT-013 acts at the level of formation, function and clearance of
neutrophil extracellular traps (NETs). The publication describes 5 non-clinical in vivo
pharmacological studies, as well as human Rheumatoid Arthritis (RA), Systemic lupus
erythematosus (SLE) and mouse in vitro NET formation pharmacology. Besides Citryll’s
R&D team in Oss, 3 established academic collaborators in Germany and the US were
involved” says CSO Renato Chirivi.
“NETs are shown to play important roles in different human pathologies with high unmet
need including autoimmunity and organ damage like in SLE, RA, vasculitis, wound healing
and cancer. The new scientific publication captures the data that made us and our investors
decide to invest in the CIT-013 programme and start formal development in the spring of
2019”, says CEO Helmuth van Es.
Citryll BV is a private pharmaceutical company based at Pharmaceutical and
Biotech Campus Pivot, Park in Oss, the Netherlands. Citryll is dedicated to the development
and commercialization of therapeutics that target the innate immune system in particular
NET formation and NETs. Citryll was founded by Helmuth van Es, CEO Citryll who is cofounder
of Galapagos, Audion Therapeutics, Antabio and Effecta Pharma), and Renato
Chirivi, CSO Citryll and co-inventor of Citryll’s therapeutic antibodies, and ModiQuest B.V.,
originator of the early tACPA patents, (www.citryll.com).